Evidence map›Paper›PMID 31081043›Full record

ArticleInternational journal of oncology2019

TGF-β-induced long non-coding RNA MIR155HG promotes the progression and EMT of laryngeal squamous cell carcinoma by regulating the miR-155-5p/SOX10 axis.

Weina Cui, Wenxia Meng, Lei Zhao, Huan Cao, Weiwei Chi, Baoshan Wang

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Weina CuiDepartment of Otorhinolaryngology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Wenxia MengDepartment of Otorhinolaryngology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Lei ZhaoDepartment of Otorhinolaryngology, The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China.
Huan CaoDepartment of Otorhinolaryngology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Weiwei ChiDepartment of Otorhinolaryngology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China.
Baoshan WangDepartment of Otorhinolaryngology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.
Second Hospital of Hebei Medical University · CNAffiliated Hospital of Hebei University · CNFirst Affiliated Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑coding RNAs, particularly long non‑coding RNAs (lncRNAs), play important roles in tumorigenesis. The miR‑155 host gene (MIR155HG) lncRNA has been found to play a crucial role in tumor progression. However, the role of MIR155HG in laryngeal squamous cell carcinoma (LSCC) remains unclear. Thus, the aim of the present study was to explore the roles and underlying molecular mechanisms of action of MIR155HG and miR‑155‑5p in LSCC, in an effort to provide novel approaches for the antitumor therapy for LSCC. In the present study, the expression levels of miR‑155‑5p and MIR155HG were detected by reverse tran-scription‑quantitative polymerase chain reaction. In addition, the biological functions of MIR155HG and miR‑155‑5p on LSCC were evaluated in vitro by MTS assay, colony formation assay and Transwell assays, and in vivo by tumorigenesis assays. It was revealed that MIR155HG and miR‑155‑5p were significantly upregulated in LSCC tissues, and were associated with the TNM stage, pathological differentiation and lymph node metastasis. Moreover, the knockdown of MIR155HG and miR‑155‑5p inhibited the proliferation, migration and invasion of LSCC cells, whereas their overexpression exerted the opposite effects in vitro and MIR155HG overexpression promoted tumorigenesis in vivo. Furthermore, MIR155HG downregulation reduced the expression level of miR‑155‑5p. The inhibitory effect of MIR155HG knockdown on malignant behavior was abrogated by miR‑155‑5p overexpression. Bioinformatics analysis and luciferase reporter assay confirmed that miR‑155‑5p contributed to the progression of LSCC by directly binding to the 3' untranslated region of SRY‑related‑HMG‑box 10 (SOX10). In addition, MIR155HG and miR‑155‑5p were upregulated by the induction of transforming growth factor‑β (TGF‑β) and promoted the expression of mesenchymal markers synergistically. On the whole, the findings of the present study indicate a novel role of MIR155HG in the TGF‑β‑induced EMT of LSCC cells by regulating EMT markers through the miR‑155/SOX10 axis. The MIR155HG/miR‑155‑5p/SOX10 axis plays an important role in promoting the progression of LSCC and may thus serve as a potential therapeutic target for LSCC treatment.

Indexed as

AnimalsCarcinoma, Squamous CellCell Line, TumorCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansLaryngeal NeoplasmsLymphatic MetastasisMaleMiceMicroRNAsNeoplasm StagingNeoplasm TransplantationRNA, Long NoncodingMicroRNAsMIRN155 microRNA, humanRNA, Long NoncodingSOX10 protein, humanSOXE Transcription FactorsTransforming Growth Factor beta

Identifiers

PMID31081043
PMCPMC6521927
OpenAlexW2938240540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.